CYCS and prostate cancer: The modified inhibitor rBbKIm, comprising RGD/RGE sequences [28], also interfered with the viability of prostate cancer cell lines DU145 and PC3, leading to cell death through the release of cytochrome c from, and caspase-3 activation in, the mitochondria [29].